Past Trials & Stats
Explorer our past clinical trials and site performance metric
Our Process
Precision, Performance, Partnership
At Optimus U, scientific rigor meets operational agility. Our team combines 11 years of research leadership with cutting-edge technologies like RealTime CTMS, Signant eCOA, and remote monitoring systems—all Part 11 compliant. From rapid IRB turnaround to 95% participant retention, every process is designed to drive faster enrollments, cleaner data, and unmatched protocol compliance. Sponsors trust our track record: 98 trials completed, 29 audits passed, and 2 FDA inspections with No Action Indicated
98
Trials Completed
95%
Retentions Rate
0.7%
Protocol Deviations
29%
Screen Fall Rate
Our Values
Completed Trials & Performance Insightsble
01.
Trials Completed
98 clinical trials under the leadership of the Principal Investigator
02.
Retention Rate
95% participant retention, as featured on the homepage metric strip
03.
Protocol Deviations
0.7% deviation rate across the last 10 trials
04.
Audit Performance
67 sponsor audits with no action indicated
05.
FDA Compliance
2 FDA inspections (2019, 2024) — No Action Indicated
Equipment
Therapeutic Area
Therapeutic Area
Neurology & Neuro‑degeneration
Representative Indications Covered
Alzheimer’s disease (multiple Phase 2–3 and biomarker studies); early Parkinson’s disease
Years of Experience
2015– 2025
Psychiatry / CNS
Bipolar I mania; major depressive disorder (adjunctive & relapse‑prevention programs); agitation in Alzheimer’s, psychosis in AD
2018 – 2025
Dermatology & Pruritic Disorders
Atopic dermatitis; CKD‑associated pruritus; chronic pruritus in dialysis; nemolizumab in severe pruritus
2016 – 2023
Gastroenterology & Hepatology
IBS‑C; GERD; NASH/NAFLD (≥10 protocols, incl. Phase 3); liver fibrosis; GI motility disorders
2015 – 2025
Endocrinology & Metabolic Disease
Obesity (semaglutide, survodutide, maridebart cafraglutide, etc.); type 2 diabetes; hyperkalemia; PCOS‑linked NAFLD
2016 – 2025
Cardiology / Vascular & Imaging
Cardiovascular inflammation reduction; myocardial perfusion PET; CV‑safety in obesity/CKD, HTN
2016 – 2024
Nephrology / Renal
Hemodialysis pruritus; diabetic kidney disease (ANGPTL3 siRNA ± evinacumab); hyperkalemia in heart failure
2018 – 2025
Respiratory & Immunology
Moderate–severe asthma (povorcitinib, PT027); inhaled ciclesonide for COVID‑19
2019 – 2023
Infectious Diseases & Vaccinology
Antivirals & mAbs for COVID‑19 (ACTIV‑2, COMET series, GS‑5245); *C. difficile*; RSV & influenza mRNA vaccines; ABSSSI; bacteremia
2018 – 2023
Hematology
Iron‑deficiency anaemia (pediatric ferumoxytol)
2019- present
Women’s Health / Endocrine
Saroglitazar in NAFLD among women with PCOS
2020
Diagnostics, Imaging & Biomarkers
Flurpiridaz PET; [18F]PI‑2620 tau PET; plasma amyloid panels; smartphone cognitive self‑assessments
2019 – 2025
